Lung Cancer | Cancer Types - National Foundation for Cancer Research

Lung Cancer

Hundreds of thousands of people are diagnosed with lung cancer in the U.S. each year. Thankfully, researchers are making great strides in understanding this disease and how to more effectively treat it.

Key Facts

  • In the U.S., an estimated 238,340 people will receive a diagnosis of lung cancer this year.
  • Lung cancer is the second most common cancer in both men and women and expects to claim 127,070 lives in 2023 in the U.S.
  • While cigarette smoking is the number one risk factor for lung cancer, almost 20% of lung cancer cases occur in non-smokers.  
  • Only 24% of people with lung cancer receive the diagnosis at the earliest stage, when the disease is most treatable. The five-year survival for early stage, localized lung cancer is 61%.
  • Currently, a low-dose CT scan is the only proven effective way to screen for lung cancer.
Source: American Cancer Society’s Cancer Facts & Figures 2023

Signs and Symptoms

  • A cough that does not go away or gets worse
  • Coughing up blood or rust-colored sputum (spit or phlegm)
  • Chest pain that is often worse with deep breathing, coughing, or laughing
  • Hoarseness
  • Loss of appetite
  • Unexplained weight loss
  • Shortness of breath
  • Feeling tired or weak
  • Infections such as bronchitis and pneumonia that don’t go away or keep coming back
  • New onset of wheezing
Source: American Cancer Society
Lung Cancer Location
new cases expected in 2023
deaths annually
of cases detected early
Silver Brain Cancer Ribbon

Lung Cancer Awareness Month is recognized in November. To help accelerate cures please make a gift today.

Researchers Working on Lung Cancer

Wei Zhang, Ph.D.
Wake Forest Baptist Medical Center
Michael B. Sporn, M.D.
Geisel School of Medicine
Daniel Von Hoff, M.D
Translational Genomics Research Institute (TGen)
Aaron N. Hata, M.D., Ph.D.
Aaron N. Hata, M.D., Ph.D. Harvard Medical School and Massachusetts General Hospital
Jessica J. Lin, M.D.
Jessica J. Lin, M.D. Harvard Medical School and Massachusetts General Hospital
Daniel A. Haber, M.D., Ph.D.
Massachusetts General Hospital Cancer Center
Susan B. Horwitz, Ph.D.
Albert Einstein College of Medicine
Amos B. Smith III, Ph.D.
University of Pennsylvania
Alice T. Shaw, M.D., Ph.D.
Massachusetts General Hospital

Related Content

New Treatment with Combined Immunotherapies is Effective for Drug Resistant Metastatic Lung Cancer

Immune checkpoint inhibitor (ICI) drugs, such as the PD-1inhibitors nivolumab and pembrolizumab, have provided unprecedented survival to patients in many types of cancer in recent years and are used for late-stage cancer treatment worldwide. Unfortunately, many patients who responded well to initial treatments gradually developed drug resistance, which resumed cancer progression.  Tumor-infiltrating lymphocyte (TIL) therapy is a new type of immunotherapy. Unlike the antibody-based ICI drugs, TIL therapy is a cell-based therapy that uses a particular group of immune T-cells obtained from a patient’s own tumor tissues to treat their cancers.  The Clinical Trial on TIL Therapy As TIL therapy has demonstrated its effectiveness in treating melanoma and other malignancies, oncologists at the H. Lee Moffitt Cancer Center & Research Institute in Florida are conducting a phase 1 clinical trial to see if combining the TIL therapy with the ICI drug nivolumab could help address the drug resistance problem for patients with metastatic non-small cell lung cancer. The clinical trial involved those patients who had developed initial progression under the monotherapy of PD-1 inhibitor nivolumab. Special immune T-cells were taken from patient’s tissues that were surgically removed from their tumors. These T-cells were grown to very large numbers (up to billions) in the laboratory and then infused back into the patients to let them seek and attack cancer cells inside their bodies.  Encouraging Results of the Clinical Trial In early August 2021, very encouraging clinical trial results were published in the elite research journal Nature Medicine. Among the 13 evaluable patients, 11 had about a 35% reduction in tumor size (measured by “median best change”). Furthermore, two patients achieved durable complete responses that were ongoing 1.5 years later. From these results, the researchers believe that TIL therapy is generally safe and could be a promising new treatment option for metastatic non-small cell lung cancer.  New Hope for Lung Cancer Patients Additional data will be obtained from this clinical trial and analyzed by the team at Moffitt Cancer Center. We look forward to seeing more positive results soon, which will bring more good news and new hope to lung cancer patients. To learn more about TIL therapy, watch our video with a real-life testimonial from a late-stage cancer patient here. Additional Reads You May Enjoy: Innovative Research and New Drug Development Continue to Prolong Survival Time of Lung Cancer Patients Small Cell Lung Cancer vs. Non-small Cell Lung Cancer: What’s the Difference? NFCR-Supported Researcher Leads Study Aiming to Understand Which Patients May Respond Best to Immunotherapy Stay up-to-date with the latest information on new drug development. Receive our monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips, and more; sign up here.  References: Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nature Medicine, August 12, 2021.

Innovative Research and New Drug Development Continue to Prolong Survival Time of Lung Cancer Patients

Lung Cancer is the deadliest type of cancer in the US. The American Cancer Society estimates that about 132,000 people will die of the disease in 2021. Thanks to the constant progress of innovative research and new drug development, mortality rates of lung cancer — especially non-small cell lung cancer (NSCLC) — have reduced sharply in recent years. The reduction is attributed mainly to several novel treatment options that became available for patients.  Fifteen years ago, treatment options for lung cancer were very limited: There were only a few chemotherapy regimens available to choose from for oncologists. But today, in addition to those chemotherapy agents, multiple mutation-specific targeted therapy drugs and immune checkpoint inhibitors (ICIs) have been approved by the US FDA for the first-line treatment of lung cancer, either used as a single agent or in a combinational treatment regimen.  Therefore, targeted therapy and ICIs-based immunotherapy are the two major contributors responsible for the reduced lung cancer mortality rate and prolonged survival time of lung cancer patients. At the 2021 American Society of Clinical Oncology (ASCO) virtual conference, encouraging data was presented showing that steady progress in developing targeted therapy and immunotherapy is being made in the following areas for the treatment of lung cancer:  Survival benefits for advanced-stage NSCLC patients: Compared to chemotherapy alone, the first-line treatment by the ICIs drugs nivolumab and ipilimumab offered the benefit of overall survival to the patients with advanced-stage NSCLC. The long-term survival benefit is demonstrated by the four-year follow-up data from the clinical trial Checkmate 227. Survival benefits for patients with unresectable stage III NSCLC:  the clinical trial PACIFIC’s five-year update data showed that compared with placebo groups, about 43% of patients who received treatment of ICIs drug durvalumab remain alive after five years, and approximately one-third of those patients have no evidence of disease progression.  New drug targeting the NSCLC with KRAS-mutation was approved: sotorasib is a new treatment for NSCLC with the specific mutation KRAS G12C. This new targeted therapy drug was recently approved by the FDA in May 2021.  The following targeted therapy drugs are being actively developed in clinical trials: Poziotinib, a new drug targeting the NSCLC with insertion mutation EGFRex20ins, has demonstrated durable benefit with patients whose cancers had progressed on chemotherapy.  MET-alteration-targeting drugs capmatinib and tepotinib have shown promising data in their clinical trials for treating advanced NSCLC with MET mutations. These new drugs will continue to bring down the mortality rates of lung cancer and further prolong the survival time of NSCLC patients. Innovative research advances are surely bringing the hope of making lung cancer a chronical disease one step closer to lung cancer patients around the world.   To stay up-to-date with the latest information on new drug development, receive our monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips, and more; sign up here.  Additional Reads You May Enjoy: Small Cell Lung Cancer vs. Non-small Cell Lung Cancer: What’s the Difference? Why is Lung Cancer So Deadly? New Device Means Better Lung Cancer Treatment Faster References: New treatments spur sharp reduction in lung cancer mortality rate. News Release, National Cancer Institute, Wednesday, August 12, 2020. [...]

Lung Cancer Awareness Month: Wildfires and Cancer

It’s already November and the dystopian year of 2020 has hardly been mundane. The year began with Australia ablaze, sending the world into a panic about the wellbeing of Australians and their notorious animals. As the year continued, health and wellbeing remained a priority for people around the world. Now, as the west coast is affected by disastrous wildfires, questions of health begin to arise once again. What’s the risk? Many people affected by the wildfires have expressed concerns about the long-term impacts the smoke may have on their health and how they can protect themselves and their family. The smoke from wildfires may have long-term health effects, but healthcare professionals advise that it is actually particles within the smoke that cause the biggest threat. Most smoke is filled with ash and debris, which can be harmful to ones’ health. Wildfire smoke, however, is particularly dangerous as the debris comes from a variety of burnt material, including appliances, home structures, and vehicles. Because there is such a large variety of burnt material, it is difficult to know exactly what is being inhaled, and therefore, how much of a cancer risk it may pose. Researchers have been curious about the cancerous effects of wildfire smoke on proximate citizens, but there is limited data available regarding length of exposure. Most published studies that have identified a link between wildfire smoke and an increased lung cancer risk have involved firefighters. These studies suggest that there is, in fact, a correlation between wildfire smoke and cancer; however the majority of the participants endured prolonged exposure. More data is required to determine the correlation of cancer risk with short-term exposure. How can I protect myself? As researchers continue to determine the risk wildfire smoke bears, the National Foundation for Cancer Research recommends taking precautions when exposed to wildfire smoke. Breathing in the ash and debris may pose a cancer risk, but it also has been linked to heart disease, COPD, and other respiratory conditions. To protect oneself, the US Centers for Disease Control and Prevention (CDC) suggests wearing a heavy-duty mask called a respirator when outdoors near smoke for an extended period of time. These masks are more protective than paper dust masks, which look like surgical masks, as they can trap smaller particles common in wildfire smoke. Staying inside can be a safe option if the air quality is low but the fires don’t present immediate danger to the area. When staying inside, it is important to keep doors and windows closed and secure and to run an air conditioner with the fresh air intake closed. Clean air conditioner filters will also help clear any debris or particles that may be in the air. It is also advised that families avoid vacuuming as it can redistribute settled particles into the air. For cancer patients or people who already have asthma or another lung disease, it is important to speak to a doctor to develop an action plan. Having an action plan ready, including an emergency contact, list of medications, and evacuation plan, can save time and help one’s family think quickly and clearly in […]